SCHEMBL486258

SCHEMBL486258

O=C(NC1CCC1)c1sc2ccccc2c1OCc1nc2ccccc2s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.52
NPC1 O15118 7/20 0.48
RAB9A P51151 6/20 0.48
CXCR6 O00574 1/20 0.48
ALOX5 P09917 3/20 0.45
EPHX2 P34913 2/20 0.45
ALOX5AP P20292 1/20 0.45
FEN1 P39748 1/20 0.45
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 3/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
SMN1; SMN2 Q16637 5/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL485447 0.98 MAOB (0.50) MAOBNPC1RAB9ACXCR6ALOX5
Formic Acid SCHEMBL27693254 0.96 MAOB (0.48) MAOBNPC1RAB9ACXCR6ALOX5
SCHEMBL486027 0.86 MAOB (0.50) MAOBNPC1RAB9ACXCR6ALOX5
SCHEMBL485598 0.84 MAOB (0.53) MAOBNPC1RAB9ACXCR6ALOX5
Formic Acid SCHEMBL27693206 0.83 MAOB (0.47) MAOBNPC1RAB9ACXCR6ALOX5
SCHEMBL486121 0.83 MAOB (0.47) MAOBNPC1RAB9ACXCR6ALOX5
SCHEMBL485827 0.82 MAOB (0.47) MAOBNPC1RAB9ACXCR6ALOX5
SCHEMBL485800 0.81 KMT2A (0.49) MAOBNPC1RAB9ACXCR6ALOX5
Formic Acid SCHEMBL28768792 0.81 MAOB (0.45) MAOBNPC1RAB9ACXCR6ALOX5
Bicarbonate SCHEMBL485659 0.81 ALOX5 (0.48) MAOBNPC1RAB9ACXCR6ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836158-B1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION SANOFI AVENTIS DEUTSCHLAND (DE) 2012-02-01 EP claimed